Title |
Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled study
|
---|---|
Published in |
BMC Musculoskeletal Disorders, April 2011
|
DOI | 10.1186/1471-2474-12-71 |
Pubmed ID | |
Authors |
Gelsomina L Borromeo, Caroline Brand, John G Clement, Michael McCullough, Wendy Thomson, Elly Flitzanis, John D Wark |
Abstract |
Bisphosphonates are common first line medications used for the management of benign bone disease. One of the most devastating complications associated with bisphosphonate use is osteonecrosis of the jaws which may be related to duration of exposure and hence cumulative dose, dental interventions, medical co-morbidities or in some circumstances with no identifiable aggravating factor. While jaw osteonecrosis is a devastating outcome which is currently difficult to manage, various forms of delayed dental healing may be a less dramatic and, therefore, poorly-recognised complications of bisphosphonate use for the treatment of osteoporosis. It is hypothesised that long-term (more than 1 year's duration) bisphosphonate use for the treatment of post-menopausal osteoporosis or other benign bone disease is associated with impaired dental healing. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 2 | 4% |
Taiwan | 1 | 2% |
Unknown | 54 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 9 | 16% |
Student > Master | 7 | 12% |
Professor > Associate Professor | 6 | 11% |
Student > Doctoral Student | 6 | 11% |
Researcher | 4 | 7% |
Other | 12 | 21% |
Unknown | 13 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 30 | 53% |
Agricultural and Biological Sciences | 4 | 7% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
Immunology and Microbiology | 2 | 4% |
Unspecified | 1 | 2% |
Other | 4 | 7% |
Unknown | 13 | 23% |